Summary of Arcturus Therapeutics Conference Call Company Overview - **Company**: Arcturus Therapeutics (NasdaqGM:ARCT) - **Event**: 2026 Conference on March 11, 2026 Key Points on Cystic Fibrosis (CF) Program - **Phase 2 Study Progress**: Completed three cohorts with successful dosing at 5 mg, 10 mg, and 15 mg, showing consistent tolerability across all levels [3][4] - **Study Duration**: The initial studies were 28-day trials, with plans to advance to a 12-week study to assess lung function improvements [4][5] - **Clinical Signals**: Early signals of biological proof of concept were observed, including decreases in mucus plugging as seen in high-resolution CT scans [4][5] - **Study Design Learnings**: The design of the upcoming 12-week study will incorporate multiple baseline measurements for lung function to control variability [10][11] - **Patient Selection**: The criteria for patient selection in the 12-week study will be narrowed to focus on subjects with moderate lung function, enhancing the potential for observable improvements [12][13] - **Endpoints**: The study will evaluate multiple endpoints, including FEV, LCI, and quality-of-life measures, alongside imaging data from CT scans [13][14] - **Regulatory Path**: The company anticipates leveraging data from a natural history study conducted by the CF Foundation for potential Phase 3 studies, depending on the outcomes of the 12-week study [35][36] Key Points on OTC Program - **Regulatory Clarity**: The company is seeking clarity from the FDA regarding the regulatory path for treating Ornithine Transcarbamylase deficiency, particularly in pediatric patients [42][43] - **Focus on Pediatric Population**: There is a strong emphasis on addressing the unmet medical needs of children, with plans to prioritize pediatric development [56][59] - **Innovative Assay**: Introduction of a new 15N ureagenesis assay to assess ammonia control in severe pediatric cases, which is a significant concern [50][52] Key Points on Respiratory Vaccine Franchise - **KOSTAIVE Updates**: The vaccine has received approval in the UK and is under arbitration regarding a milestone payment from CSL related to EU approval [65][70] - **Impact of Arbitration**: The outcome of the arbitration could significantly affect the company's cash runway, which currently extends to Q2 2028 without including potential milestone payments [75][76] Additional Insights - **Market Dynamics**: The company is expanding its CF study sites to Europe and the Middle East due to a higher prevalence of Class 1 CF subjects in those regions compared to the U.S. [33][34] - **Future Data Sharing**: The company plans to share data from the 12-week study after a certain number of subjects have been enrolled, although specific timelines have not been provided [39][40] - **Investor Communication**: The company is committed to keeping investors informed about ongoing developments and regulatory interactions, particularly regarding the OTC program and CF studies [72][73]

Summary of aTyr Pharma (ATYR) 2025 Conference Call Company Overview - **Company**: aTyr Pharma (ATYR) - **Event**: 2025 Jefferies Global Healthcare Conference - **Focus**: Lead program for pulmonary sarcoidosis and updates on other indications Key Points on Pulmonary Sarcoidosis Program - **Phase Three Study**: Baseline demographics presented at ATS, showing expected characteristics in race, gender, and age of sarcoidosis patients [3][4] - **Steroid Dosage**: Average steroid dose at entry for the phase three trial was 10.5 mg, slightly lower than the 12-13 mg in phase two, aligning with treatment guidelines [4][6] - **Patient Management**: Patients on lower steroid doses are more sensitive to reductions, with a focus on managing flare-ups in the placebo group [12][13] - **FDA Feedback**: FDA recommended simplifying the statistical analysis plan to focus on the last four weeks of treatment, which increases the power to detect smaller differences [17][18] - **Power Assumptions**: The trial is powered to show a statistically significant absolute reduction of 3 mg in steroid use compared to placebo [22][23] - **Market Opportunity**: The target population for the therapy is larger than initially estimated, with 150,000 to 160,000 steroid-dependent patients in the U.S. [48][49] Other Indications and Updates - **Scleroderma-Related ILD Study**: Interim data showed promising results in skin improvement, particularly in diffuse scleroderma patients [60][62] - **Potential for Broader Applications**: Interest in expanding the use of epsofitimod to other forms of interstitial lung disease (ILD) and connective tissue disease ILD, with a potential market value exceeding $5 billion [70][71] Financial Position - **Cash Position**: The company has sufficient cash to support operations through the upcoming readouts and for at least another year beyond that [72] Conclusion - aTyr Pharma is positioned to potentially change treatment paradigms in pulmonary sarcoidosis and other ILDs, with significant market opportunities and a strong financial position to support ongoing and future trials.